A Ministry of Commerce spokesperson did not mention any U.S. actions specifically, but it's been a tense couple of weeks for the trade negotiations.World Politicsread more
U.S. stock index futures were lower Thursday morning, as market participants continue to monitor an intensifying trade war between the world's two largest economies.US Marketsread more
British Prime Minister Theresa May could announce her resignation in the next few days, according to U.K. media reports, as she faces increasing pressure from members of her...Europe Politicsread more
A federal judge in New York City on Wednesday said Deutsche Bank and Capital One can turn over financial documents related to President Donald Trump and his businesses in...Politicsread more
Chinese government-aligned experts are stressing that the U.S. will need to negotiate a trade agreement with Asia's largest economy.China Economyread more
Escalating trade tensions have hit emerging markets hard this month. With the trade war still a looming fear for markets, Miller Tabak equity strategist Matt Maley is making a...Trading Nationread more
Under-the-radar hedge-fund managers beating the market are betting on big comeback stories General Electric and PG&E, as well as Biogen.Marketsread more
Richard Yu, CEO of Huawei's consumer business, said Huawei's own operating system for smartphones and laptops could be ready for use in China by fall this year.Technologyread more
Best Buy beat Wall Street estimates for quarterly same-store sales on Thursday, as the consumer electronics retailer sold more wearables and tablets and signed up more people...Retailread more
Shares of L Brands, the owner of Victoria's Secret and Bath & Body Works, rose nearly 11% in aftermarket trading Wednesday after the company reported it beat revenue and...Retailread more
The global economy would be hit hard if President Donald Trump decides to impose steep tariffs on imported cars, Citi's Willem Buiter told CNBC on Thursday, with Germany...Autosread more
Grail, the cancer detection start-up backed by tech giants Alphabet and Amazon, is already seeking new funding, mere months after it closed a $900 million round in March. The company had previously raised $100 million in 2016.
Grail is primarily pitching sovereign funds, with mixed success, according to two sources familiar. It has approached Softbank and Mubadala, Abu Dhabi's $125 billion sovereign fund, according to one of the people.
The start-up is primarily planning to use the funds for its massive breast cancer trial that it announced in April of this year. That study involves analyzing the blood of 120,000 women in many different locations.
But the company has also had some other expenses that may be pushing it back to the fund-raising market.
Grail announced in March that some of the proceeds from its financing would be used to buy a large portion of its shares from parent company Illumina, reducing Illumina's ownership to a minority stake. The aggregate purchase price was $278 million, according to a public filing.
It also shelled out more than $100 million to merge with a Chinese company called Cirina, according to one of the sources. Cirina is developing an early-stage commercial test for a type of cancer called nasopharyngeal carcinoma.
Additional funds were earmarked for another expensive clinical study, its Circulating Cell-Free Genome Atlas Study (CCGA), which involves enrolling 10,000 participants. This study is meant to give Grail a more detailed map of cancer genetics.
The company declined to comment on its financing plans, but said "we are always in touch with the capital markets."
Meanwhile, the company has seen multiple senior leaders depart in recent months, including former CEO Jeff Huber, formerly of Google; data scientist Franz Och; and former head of clinical development Mark Lee. These departures were previously reported by Buzzfeed. Business development lead Elaine Cheung also departed recently, according to her LinkedIn profile.
When Grail burst onto the scene in 2016, it announced an ambitious objective to have its first test on the market within three years.
The idea behind such early-detection tests, which are in development by Grail and its chief competitors Guardant Health and Freenome, is to catch cancer early by picking up signals of free-floating tumor DNA in the bloodstream. The hope is that at that point, it would be easier and cheaper to treat.
The biggest challenges to get these tests to market include price -- the tests might be too expensive to get covered by insurers -- and high rates of both false positives and negatives. For that reasons, these companies need to invest heavily on clinical studies.